Læknablaðið - 15.10.1998, Qupperneq 23

LÆKNABLAÐIÐ 1998; 84
735
krabbameinsrannsóknir á Islandi, Reykjavík 1998 [ágrip].
Læknablaðið 1998; 84: 385.
53. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, Mc
Guire WL. Prognostic significance of p53 gene alterations
in node-negative breast cancer. Breast Cancer Res Treat
1993; 26: 225-35.
54. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER,
Steele G Jr, et al. The DCC protein and prognosis in colo-
rectal cancer. N Engl J Med 1996; 335: 1727-32.
55. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,
McGuire WL. Human breast cancer: correlation of relapse
and survival with amplification of the HER-2/neu onco-
gene. Science 1987; 235: 177-82.
56. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC,
Osbome CK, et al. HER2/neu in node-negative breast canc-
er: prognostic significance of overexpression influenced by
the presence of in situ carcinoma. J Clin Oncol 1992; 10:
599-605.
57. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-
Soderborgh J, Anbazhagan R, et al. Prognostic importance
of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;
10: 1049-56.
58. Muss HB,Thor AD, Berry DA, KuteT, Liu EdisonT, Koer-
ner R, et al. c-erbB-2 expression and response to adjuvant
therapy in women with node-positive early breast cancer. N
EnglJMed 1994; 330: 1260-6.
59. Thorlacius S, Þorgilsson B, Bjömsson J, Tryggvadóttir L,
Borresen AL, Ögmundsdóttir HM, et al. TP53 mutations
and abnormal p53 protein staining in breast carcinomas re-
lated to prognosis. Eur J Cancer 1995; 31A: 1856-61.
60. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L.
Complete sequencing of the p53 gene provides prognostic
information in breast cancer patients, particularly in rela-
tion to adjuvant systemic therapy and radiotherapy. Nature
Med 1995; 1: 1029-34.
61. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen
H, Varhaug JR, et al. Specific p53 mutations are associated
with de novo resistance to doxorubicin in breast cancer
patients. Nature Med 1996; 2: 811-4.
62. Shelling AN. Role of p53 in drug resistance in ovarian
cancer. Lancet 1997; 349: 744-5.
63. Figueroa JA, Yee D, McGuire WL. Prognostic indicators in
early breast cancer. Am J Med Sci 1993; 305: 176-82.
64. Sigurðsson H, Baldetorp B, Borg A, Dalberg M, Femo M,
Killander D, et al. Indicators of prognosis in node-negative
breast cancer. N Engl J Med 1990; 323: 1348-50.
65. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla
Palma P, Caffo O, et al. Tumor microvessel density, p53 ex-
pression, tumor size and peritumoral lymphatic cell inva-
sion are relevent prognostic markers in node-negative
breast carcinoma. J Clin Oncol 1994; 12: 454-66.
66. Potosky AL, Miller BA, Albertson PC, Kramer BS. The role
of increasing detection in the rising incidence of prostate
cancer. JAMA 1995; 273: 548-52.
67. Johansson JE, Adami HO, Anderson SO, Bergström R,
Holmberg L, Kmsemo UB. High 10 year survival rate in
patients with early, untreated prostatic cancer. JAMA 1992;
267:2191-6.
68. Sigurðsson S, Thorlacius S, Tómasson J, Tryggvadóttir L,
Benediktsdóttir K, Eyfjörð J, et al. BRCA2 mutation in Ice-
landic prostate cancer patients. J Mol Med 1997; 75: 758-61.
69. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA,
Shane S, et al. Residual disease at the end of induction the-
rapy as a predictor of relapse during therapy in childhood
B-lineage acute lymphoblastic leukemia. J Clin Oncol
1992; 10: 1879-88.
70. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V,
Avvisati G, et al. Molecular evaluation of residual disease
as a predictor of relapse in acute promyelocytic leukaemia.
Lancet 1992; 340: 1437-8.
Fræðigreinar fslenskra lækna f erlendum tfmaritum
* Helga Hannesdóttir. Approaches to the
Development of Mental Health Systems for
Children in the Nordic Countries. In: Young
JG, Ferrari P. Mental Health Sevices and Sys-
tems for Children and Adolescents. Phila-
delphia: Brunner/Mazel 1998.
* Jón Snædal, Jakob Kristinsson, Sjöfn
Gunnarsdóttir, Aslaug Ólafsdóttir, Magnús
Baldvinsson, Þorkell Jóhannesson. Copper,
Ceruloplasmin and Superoxide Dismutase in
Patients with Alzheimer’s Disease. Dement
Geriatr Cogn Disord 1998; 9: 239-42.
* Þorbjörn Jónsson, Halldór Baldursson.
Vágen till med.dr. pá Island. Bibliotek for
Læger, juni 1998: 148-54.